![Next generation antibody drug conjugates (ADCs) and immunotoxins [electronic resource]](https://image.aladin.co.kr/product/9108/60/cover/3319468758_2.jpg)
| 000 | 00000cam u2200205 a 4500 | |
| 001 | 000046011754 | |
| 005 | 20200121160704 | |
| 006 | m d | |
| 007 | cr | |
| 008 | 200107s2017 sz a ob 001 0 eng d | |
| 020 | ▼a 9783319468754 | |
| 020 | ▼a 9783319468778 (e-book) | |
| 040 | ▼a 211009 ▼c 211009 ▼d 211009 | |
| 050 | 4 | ▼a RM1-950 |
| 082 | 0 4 | ▼a 615.798 ▼2 23 |
| 084 | ▼a 615.798 ▼2 DDCK | |
| 090 | ▼a 615.798 | |
| 245 | 0 0 | ▼a Next generation antibody drug conjugates (ADCs) and immunotoxins ▼h [electronic resource] / ▼c Ulf Grawunder, Stefan Barth, editors. |
| 246 | 3 0 | ▼a ADCs |
| 260 | ▼a Cham : ▼b Springer, ▼c c2017. | |
| 300 | ▼a 1 online resource (xi, 181 p.) : ▼b ill. (some col.). | |
| 490 | 1 | ▼a Milestones in Drug Therapy, ▼x 2296-6056, ▼x 2296-6064 (electronic) |
| 500 | ▼a Title from e-Book title page. | |
| 504 | ▼a Includes bibliographical references and index. | |
| 505 | 0 | ▼a Chemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P – Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22. |
| 520 | ▼a This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology. | |
| 530 | ▼a Issued also as a book. | |
| 538 | ▼a Mode of access: World Wide Web. | |
| 650 | 0 | ▼a Toxicology. |
| 650 | 0 | ▼a Monoclonal antibodies. |
| 650 | 0 | ▼a Oncology. |
| 700 | 1 | ▼a Grawunder, Ulf. |
| 700 | 1 | ▼a Barth, Stefan. |
| 830 | 0 | ▼a Milestones in Drug Therapy. |
| 856 | 4 0 | ▼u https://oca.korea.ac.kr/link.n2s?url=https://doi.org/10.1007/978-3-319-46877-8 |
| 945 | ▼a KLPA | |
| 991 | ▼a E-Book(소장) |
소장정보
| No. | 소장처 | 청구기호 | 등록번호 | 도서상태 | 반납예정일 | 예약 | 서비스 |
|---|---|---|---|---|---|---|---|
| No. 1 | 소장처 중앙도서관/e-Book 컬렉션/ | 청구기호 CR 615.798 | 등록번호 E14018695 | 도서상태 대출불가(열람가능) | 반납예정일 | 예약 | 서비스 |